These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19781516)

  • 21. Pharmaceutical transition to non-CFC pressurized metered dose inhalers.
    Cripps A; Riebe M; Schulze M; Woodhouse R
    Respir Med; 2000 Jun; 94 Suppl B():S3-9. PubMed ID: 10919679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers.
    Gabrio BJ; Stein SW; Velasquez DJ
    Int J Pharm; 1999 Sep; 186(1):3-12. PubMed ID: 10469919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone.
    Leach CL; Davidson PJ; Boudreau RJ
    Eur Respir J; 1998 Dec; 12(6):1346-53. PubMed ID: 9877489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plume temperature emitted from metered dose inhalers.
    Brambilla G; Church T; Lewis D; Meakin B
    Int J Pharm; 2011 Feb; 405(1-2):9-15. PubMed ID: 21129465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concepts of establishing clinical bioequivalence of chlorofluorocarbon and hydrofluoroalkane beta-agonists.
    Parameswaran K
    J Allergy Clin Immunol; 1999 Dec; 104(6):S243-5. PubMed ID: 10588983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deposition of fenoterol from pressurized metered dose inhalers containing hydrofluoroalkanes.
    Newman S; Pitcairn G; Steed K; Harrison A; Nagel J
    J Allergy Clin Immunol; 1999 Dec; 104(6):S253-7. PubMed ID: 10588986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of chlorofluorocarbon and hydrofluoroalkane metered-dose inhaler formulations of beclomethasone dipropionate.
    Lipworth BJ; Jackson CM
    Br J Clin Pharmacol; 1999 Dec; 48(6):866-8. PubMed ID: 10594492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic exposure and urinary cortisol effects of fluticasone propionate formulated with hydrofluoroalkane in 4- to 11-year-olds with asthma.
    Kim KT; Milgrom H; Yoon YK; Levy AL; Matz P; Welch MJ; Cahn A; Collins DA; Kathman S; Mehta R; Su SF; Kunka RL
    J Clin Pharmacol; 2008 Jan; 48(1):108-16. PubMed ID: 18094223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Albuterol delivery in a neonatal ventilated lung model: Nebulization versus chlorofluorocarbon- and hydrofluoroalkane-pressurized metered dose inhalers.
    Lugo RA; Kenney JK; Keenan J; Salyer JW; Ballard J; Ward RM
    Pediatr Pulmonol; 2001 Mar; 31(3):247-54. PubMed ID: 11276138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans.
    Leach C
    J Allergy Clin Immunol; 1999 Dec; 104(6):S250-2. PubMed ID: 10588985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluticasone propionate hydrofluoroalkane inhalation aerosol in patients receiving inhaled corticosteroids.
    Lumry WR; Conway MM; LaForce CF; Pearlman DS; Scott CA; Herje NE; Wu WW; Crim C
    Ann Allergy Asthma Immunol; 2006 Jan; 96(1):51-9. PubMed ID: 16440533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Withdrawal of albuterol inhalers containing chlorofluorocarbon propellants.
    Hendeles L; Colice GL; Meyer RJ
    N Engl J Med; 2007 Mar; 356(13):1344-51. PubMed ID: 17392304
    [No Abstract]   [Full Text] [Related]  

  • 33. Preparing for a change in metered-dose inhalers. National Asthma Education and Prevention Program CFC Phaseout Working Group.
    Minn Med; 1998 Feb; 81(2):26-7. PubMed ID: 9505495
    [No Abstract]   [Full Text] [Related]  

  • 34. Budesonide administered using chlorofluorocarbon and hydrofluoroalkane pressurized metered-dose inhalers: pharmacokinetics, pharmacodynamics and clinical equivalence.
    Singh D; Tutuncu A; Lohr I; Carlholm M; Polanowski T
    Int J Clin Pharmacol Ther; 2007 Sep; 45(9):485-95. PubMed ID: 17907591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Issues surrounding MDI formulation development with non-CFC propellants.
    Kontny MJ; Destefano G; Jager PD; McNamara DP; Turi JS; Van Campen L
    J Aerosol Med; 1991; 4(3):181-7. PubMed ID: 10147677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The environmental impact of chlorofluorocarbon use in metered dose inhalers.
    Balmes JR
    Chest; 1991 Oct; 100(4):1101-2. PubMed ID: 1914565
    [No Abstract]   [Full Text] [Related]  

  • 37. Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant.
    Mackie AE; McDowall JE; Ventresca P; Bye A; Falcoz C; Daley-Yates PT
    Clin Pharmacokinet; 2000; 39 Suppl 1():17-22. PubMed ID: 11140429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Compatibility evaluation of metered-dose inhaler valve elastomers with tetrafluoroethane (P134a), a non-CFC propellant.
    Tiwari D; Goldman D; Dixit S; Malick WA; Madan PL
    Drug Dev Ind Pharm; 1998 Apr; 24(4):345-52. PubMed ID: 9876594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extra-fine corticosteroid aerosols from hydrofluoroalkane-134a metered-dose inhalers: potential advantages and disadvantages.
    Tashkin DP
    Chest; 1999 Feb; 115(2):316-8. PubMed ID: 10027423
    [No Abstract]   [Full Text] [Related]  

  • 40. Development and performance of a new hydrofluoroalkane (HFA 134a)-based metered dose inhaler (MDI) of salmeterol.
    Peyron ID; Britto IL; Benissan LB; Tardieu BZ
    Respir Med; 2005 Apr; 99 Suppl A():S20-30. PubMed ID: 15777605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.